Ashion™ Advanced Individual Medicine™ (AIM) a leader in the rapidly evolving genomic medicine industry announced today the launch of its premier personalized medicine service using Syapse Precision Medicine Platform. AIM develops and manages comprehensive Personalized Medicine Centers (PMCs) with partner regional healthcare systems providing these centers with clinical guidelines laboratory recommendations genomic interpretation education and operational support. AIM will use Syapse’s precision medicine software to enable oncologists at PMCs to provide care tailored to a patient’s molecular profile while centralizing clinical data and patient outcomes from AIM’s network of PMCs to develop best practices delivered by Syapse as actionable guidance at the point of care.
With the launch of its service AIM will introduce personalized medicine cancer programs into hospitals clinics and other healthcare providers across the U.S. By connecting to providers’ electronic medical records Syapse will aggregate patients’ medical history treatments genomics and outcomes in a single system. PMC oncologists using Syapse Precision Medicine Platform will be able to access integrated molecular and clinical data order and receive results from genomic tests request guidance from an expert molecular tumor board order targeted therapies enroll patients in molecularly matched clinical trials and coordinate care across many providers and facilities. AIM will use the integrated data and workflow support provided by Syapse Precision Medicine Platform to streamline billing and reimbursement operations.
“The information we provide helps physicians establish deeper and more productive relationships with their patients” said Dr. Edgar D. Staren President at AIM. “Using Syapse software we make an abundance of clinical history genomics treatment and outcomes data accessible to the entire care team at the click of a button across a large network of Personalized Medicine Centers.”
“The opportunity to deliver healthcare in a new way for millions of people can better come to fruition as a result of this collaboration” says Dr. Michael Demeure Vice President for Genomic Medicine at AIM. “There is an essential need for the increased application of evidence-based medicine to personalized care approaches. In doing so we will more rapidly increase the quality of healthcare while at the same time reducing cost.”
“Integrating genomic data with a patient’s cancer medical record to impact treatment decisions has been an important goal of health systems since the inception of the Human Genome Project” said Jonathan Hirsch Founder and President of Syapse. “Syapse Precision Medicine Platform will help AIM create a network of Personalized Medicine Centers that will leverage clinical genomic and outcomes data across the network to rapidly improve care for patients.”
About Ashion Advanced Individual Medicine
Advanced Individual Medicine (AIM) an Ashion Company is a subsidiary of Ashion PMed Management LLC. AIM’s vision is to be recognized as the global leader in the delivery of personalized medicine solutions. AIM’s mission is to provide premier personalized medicine solutions for healthcare providers by continuously advancing the knowledge and services to the patients they serve. AIM develops and manages comprehensive Personalized Medicine Centers (PMC’s) with partner regional healthcare systems. More information is available at www.AshionAIM.com.
Press Contact:
Melissa Ray MBA BSE
Vice President Administration
Advanced Individual Medicine LLC.
MRay@AshionAIM.com
www.AshionAIM.com
